Showing 1 - 3 results of 3 for search 'Carole Schuhler', query time: 0.04s Refine Results
  1. 1
    Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling

    Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling by Felix Huth, Hilmar Schiller, Yi Jin, Birk Poller, Carole Schuhler, Wendy Weis, Ralph Woessner, Anton Drollmann, Peter End

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  2. 2
    Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial

    Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial by Martin Kaul, Peter End, Maciej Cabanski, Carole Schuhler, Annamaria Jakab, Magdalena Kistowska, Arvind Kinhikar, Alessio Maiolica, Angela Sinn, Rainard Fuhr, Bruno Cenni

    Published 2021
    Connect to this object online.
    Book
    Save to List
    Saved in:
  3. 3
    LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial

    LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial by Christian Loesche, Damien Picard, Benjamin Van Hoorick, Imelda Schuhmann, Petra Jäger, Kai Klein, Carole Schuhler, Gebhard Thoma, Christian Markert, Birk Poller, Natasa Zamurovic, H. Markus Weiss, Heike Otto, Martin Fink, Till A. Röhn

    Published 2024
    Connect to this object online.
    Book
    Save to List
    Saved in:

Search Tools: